Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RESLIZUMAB vs REVUMENIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RESLIZUMAB vs REVUMENIB: Safety Overview

Metric RESLIZUMAB REVUMENIB
Total FAERS Reports 621 371
Deaths Reported 15 49
Death Rate 2.4% 13.2%
Hospitalizations 121 93
Average Patient Age 55.9 yrs 46.4 yrs
% Female Patients 63.2% 47.6%
FDA Approval Date N/A Nov 15, 2024
Manufacturer Teva Respiratory, LLC Syndax Pharmaceuticals, Inc.
Route INTRAVENOUS ORAL
Marketing Status Prescription Prescription